ReviewThe Journal of infection2014
Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome.
Review in The Journal of infection, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 5 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Aspergillus spp. osteoarticular infections: an updated systematic review on the diagnosis, treatment and outcomes of 186 confirmed cases.Medical mycology · 2022Pooled it
- American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients.Transplantation and cellular therapy · 2021Guideline
- Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century.Medical mycology · 2017Pooled it
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- Osteoarticular Infections Caused by Non-Aspergillus Filamentous Fungi in Adult and Pediatric Patients: A Systematic Review.Medicine · 2015Pooled it
- Infectious Spondylodiscitis of Bacterial Causes in Adults: Epidemiology, Pathophysiology, Diagnostic and Treatment Challenges.Microorganisms · 2026Review
- DisseminatedFrontiers in medicine · 2026Article
- Osteomyelitis in HIV pathogenesis, challenges, and therapeutic strategies.Annals of medicine and surgery (2012) · 2026Review
- Species distribution, antifungal susceptibility, and clinical profiles of patients with osteoarticular fungal Infections: A retrospective study.New microbes and new infections · 2025Article
- Candida Spondylodiscitis After Transforaminal Epidural Steroid Injection: A Case Report.Cureus · 2025Article
- Differentiation of typical features between Fungal spondylitis and Brucellar spondylitis on CT and new applications of CT values in diagnosis of spinal infections.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025Article
- Successful Management of Spondylodiscitis Caused byJournal of fungi (Basel, Switzerland) · 2025Article
- Features of Invasive Aspergillosis Caused by Aspergillus flavus, France, 2012-2018.Emerging infectious diseases · 2025Article
- Current knowledge of vertebral osteomyelitis: a review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Spinal infection caused byFrontiers in medicine · 2025Article
- Osteoarticular mucormycosis of the distal femur in a post COVID-19 patient.Medical mycology case reports · 2024Article
- Article
- Bisphosphonates synergistically enhance the antifungal activity of azoles in dermatophytes and other pathogenic molds.mSphere · 2024Article
- An immunocompetent host with blood-disseminatedThe Journal of international medical research · 2024Review
- Pediatric Acute Mastoiditis in Saudi Arabia: Demographic Insights, Clinical Profiles, and Prognostic Factors.Children (Basel, Switzerland) · 2024Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 5 countries.
Funding
Abstract
backgroundThe epidemiology, pathogenesis, diagnosis, and management of Aspergillus osteomyelitis are not well understood.
methodsProtocol-defined cases of Aspergillus osteomyelitis published in the English literature were reviewed for comorbidities, microbiology, mechanisms of infection, clinical manifestations, radiological findings, inflammatory biomarkers, antifungal therapy, and outcome.
resultsAmong 180 evaluable patients, 127 (71%) were males. Possible predisposing medical conditions in 103 (57%) included pharmacological immunosuppression, primary immunodeficiency, and neutropenia. Seventy-three others (41%) had prior open fracture, trauma or surgery. Eighty (44%) followed a hematogenous mechanism, 58 (32%) contiguous infections, and 42 (23%) direct inoculation. Aspergillus osteomyelitis was the first manifestation of aspergillosis in 77%. Pain and tenderness were present in 80%. The most frequently infected sites were vertebrae (46%), cranium (23%), ribs (16%), and long bones (13%). Patients with vertebral Aspergillus osteomyelitis had more previous orthopedic surgery (19% vs 0%; P = 0.02), while those with cranial osteomyelitis had more diabetes mellitus (32% vs 8%; P = 0.002) and prior head/neck surgery (12% vs 0%; P = 0.02). Radiologic findings included osteolysis, soft-tissue extension, and uptake on T2-weighted images. Vertebral body Aspergillus osteomyelitis was complicated by spinal-cord compression in 47% and neurological deficits in 41%. Forty-four patients (24%) received only antifungal therapy, while 121 (67%) were managed with surgery and antifungal therapy. Overall mortality was 25%. Median duration of therapy was 90 days (range, 10-772 days). There were fewer relapses in patients managed with surgery plus antifungal therapy in comparison to those managed with antifungal therapy alone (8% vs 30%; P = 0.006).
conclusionsAspergillus osteomyelitis is a debilitating infection affecting both immunocompromised and immunocompetent patients. The most common sites are vertebrae, ribs, and cranium. Based upon this comprehensive review, management of Aspergillus osteomyelitis optimally includes antifungal therapy and selective surgery to avoid relapse and to achieve a complete response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.